QUADRA Supports Broader Use For Tesaro's PARP Inhibitor Zejula
Study in late-line use of heavily pretreated ovarian cancer may bring labeling closer in line with competitors, yet with limited commercial impact, analysts say.
You may also be interested in...
The UK major is marking its return to oncology by spending over $5bn to get hold of Tesaro and its PARP inhibitor Zejula. The question now is whether it will be able to catch AstraZeneca's market-leading Lynparza.
Gilead has once more been mentioned as a prospective acquirer of Tesaro, but analysts at Datamonitor Healthcare's PharmaVitae believe that CAR-T and NASH are the areas where the company is more likely to seek buys that reduce its reliance on hepatitis C and HIV therapies.
US FDA approval of Rubraca's all-comers maintenance therapy for platinum-sensitive ovarian cancer continues model that Zejula and Lynparza used for a broad maintenance indication, with data broken out for germline BRCA mutation-positive patients in the clinical trials section of labeling.